| B32 | Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirine | E-poster | ART in first- and second-line therapies |
| B32 | Achievement of undetectable HIV-1 RNA in the B/F/TAF treatment-naïve clinical trials | E-poster | ART in first- and second-line therapies |
| B32 | Long-term analysis of B/F/TAF in treatment-naïve adults living with HIV through four years of follow-up | E-poster | ART in first- and second-line therapies |
| B31 | OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection | E-poster | ART in acute infection |
| B30 | Rising substance use linked to STI and HCV in Thai MSM after acute HIV infection | On-demand oral abstract session | Substance abuse (including opioid use disorder) |
| B30 | Opioid agonist treatment improves progression through each stage of the HIV cascade of care among people living with HIV who use opioids | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Depression, anxiety, and polysubstance use among persons with HIV: baseline findings from the Promoting Access to Care Engagement (PACE) trial | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Results from a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Anxiety and alcohol consumption in the Miami Adult Studies on HIV (MASH) cohort during the COVID-19 pandemic | E-poster | Substance abuse (including opioid use disorder) |
| B3 | The clinical effects of durably low CD4 counts while virologically suppressed among ART-initiating persons with HIV in Latin America | On-demand oral abstract session | Determinants of HIV progression and disease control |